PROSPERO

International prospective register of systematic reviews

Inflammatory Bowel Diseases and Microbiota: A Systematic Review and Bayseian

Network Meta-analysis.
Muhammed Elhadi, Ahmed Tarek, Ahmed Abdulhamid

To enable PROSPERO to focus on COVID-19 registrations during the 2020 pandemic, this registration
record was automatically published exactly as submitted. The PROSPERO team has not checked eligibility.

Citation
Muhammed Elhadi, Ahmed Tarek, Ahmed Abdulhamid. Inflammatory Bowel Diseases and
Microbiota: A Systematic Review and Bayseian Network Meta-analysis.. PROSPERO 2020
CRD42020178919 Available from:
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020178919

Review question
What is the efficacy of microbiota in the treatment Crohn's disease and ulcerative colitis ?

Is there any different between types of microbiota used in inflammatory bowel diseases?

How the microbiota affect the remission and maintenance of Crohn's disease and ulcerative colitis ?

Searches

Search will be performed according to EMBASE, International Scientific Indexing (ISI), PubMed, Scopus,
ClinicalTrials.gov, and ScienceDirect. Additionally, hand-searching from reference lists of all related papers,
prior reviews and meta-analyses and gray literature will be performed to cover all relevant publications. We
will use search strategy for each database. The language is restricted to English. The publications are up to
November 2019 published works.

Types of study to be included

We will include randomised controlled trials that were published in peer-review journals.

Condition or domain being studied

Inflammatory intestinal disease (IBD) consists of two main disorders: ulcerative colitis and Crohn's diseases.
Ulcerative colitis involves the colon and Crohn's disease may include any part of the gastrointestinal tract.

The intestinal microbiota has physiological functions related to diet, the immune system, and the defense of
the host. Latest advances have recorded changes in IBD's structure and function of the intestinal microbiota,
defined as dysbiosis is associated with development and maintenance of IBD.

Currently, there are several studies that explore the potential effect of gut microbiota and its association with
development of IBD. Therefore, we aim to study the efficacy and health of microbiota therapy in enhancing
or reducing symptoms of patient with inflammatory bowel disease.

Participants/population
Inclusion criteria:

1- Randomized clinical trial describe the microbiota treatment of ulcerative colitis and crohn's disease.

2- No restriction regarding, age, gender, country, or ethnicity.

Exclusion criteria:

Page: 1 / 4
 PROSPERO
International prospective register of systematic reviews

1. Animal and in vitro studies.

2- Overlapping, unreliable data, or duplicated.

3- Abstract only

4. Reviews, theses, books, conference papers, letters and articles without available full texts (conferences,

editorials, author responses).

Intervention(s), exposure(s)
Microbiota including Fecal Microbiota Transplantation (FMT) and other available types.

Comparator(s)/control
Placebo or other type of treatment

Main outcome(s)
2- Asses the efficacy and safety of microbiota treatment in improving symptoms of ulcerative colitis and
crohn's disease.

2- Treatment advantages for microbiota in changing the structure of the intestinal flora.
* Measures of effect
Odds ratio (OR) and confidence intervals (CI) of 95% will be used as descriptive figures for the major
outcomes. Depending on the amount of people witnessing any of these results, probiotics is analyzed from
three perspectives: surgical recovery, endoscopic recovery / recurrence and harmful effects.

The clinical recovery for the Bayesian network was described as having an index of UC disease activity
(UCDAI) scores less than 2 in UC and obtaining an index of CD disease activity (CDAI) scores less than 150
points. Endoscopic remission in UC (Mayo endoscopic subscore = 0 or 1) has been defined as achieving
mucosal healing. In the meantime, endoscopic remission in CDs was described as getting more score than
Rutgeerts 1 (2, 3, or 4) .

Additional outcome(s)
None
* Measures of effect
Not applicable

Data extraction (selection and coding)

The following data will be extracted from eachstudy: lead author, year of publication, characteristics of
subjects, number of subjects (female and male), age, number of subjects in the intervention and control
group, type of microbiota consumed, dosage, duration, control, study design and outcomes. For the
incomplete data not clarified in the accompanying posts, writers were contacted via email or via requests to
provide data. In the event of no response, denying provision or lack of data, the missing data will be
identified as "Not specified."

If data were presented only graphically, they were extracted by using DigitizeIt® software (I. Bormann).

Risk of bias (quality) assessment

The methodological quality and the risk of bias will be conducted by two reviewers independently, in
accordance with the guidance set out in the Cochrane Handbook for Systematic Reviews of Interventions,
Version 5.1.0.15.

Page: 2 / 4
 PROSPERO
International prospective register of systematic reviews

Strategy for data synthesis

We would include a narrative overview of the outcomes from the included research, organized around the
method of intervention, characteristics of the subject population, method of result and quality of the
intervention.
The network geometry plots will be obtained from Stata version 15.0 (StataCorp) (24) and meta-analysis of
the network will be carried out in a Bayesian context using Monte Carlo's Markov chain methods in
WinBUGSversion 1.4.3 (MRC BiostatisticsUnit, Cambridge, UK).
Analysis of subgroups or subsets

Subgroup analysis will be conducted based on patients group.

Contact details for further information

Muhammed Elhadi
muhammed.elhadi.uot@gmail.com

Organisational affiliation of the review

Faculty of Medicine, University of Tripoli

Review team members and their organisational affiliations

Dr Muhammed Elhadi. Faculty of Medicine, University of Tripoli
Dr Ahmed Tarek. Faculty of Medicine, University of Tripoli
Dr Ahmed Abdulhamid. Faculty of Medicine, University of Tripoli

Type and method of review

Diagnostic, Intervention, Meta-analysis, Network meta-analysis, Systematic review

Anticipated or actual start date

10 November 2019

Anticipated completion date

10 May 2020

Funding sources/sponsors
This study did not receive any grant or funding from any department, institute or organization.
Grant number(s)
Not applicable

Conflicts of interest
The authors declare that they have no competing interests and no relationship with the industry or
organzation.
None known

Language
English

Country
Libya

Stage of review
Review Ongoing

Subject index terms status

Subject indexing assigned by CRD

Subject index terms

MeSH headings have not been applied to this record

Page: 3 / 4
 PROSPERO
International prospective register of systematic reviews

Date of registration in PROSPERO

05 July 2020

Date of first submission

08 April 2020

Stage of review at time of this submission

Stage Started Completed

Preliminary searches Yes No

Piloting of the study selection process Yes Yes

Formal screening of search results against eligibility criteria Yes No

Data extraction No No

Risk of bias (quality) assessment No No

Data analysis No No

The record owner confirms that the information they have supplied for this submission is accurate and
complete and they understand that deliberate provision of inaccurate information or omission of data may be
construed as scientific misconduct.

The record owner confirms that they will update the status of the review when it is completed and will add
publication details in due course.

Versions
05 July 2020

PROSPERO
This information has been provided by the named contact for this review. CRD has accepted this information in good
faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission
is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any
associated files or external websites.

Page: 4 / 4

Powered by TCPDF (www.tcpdf.org)